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Abstract: A series of twelve novel non-imidazole-based ligands (3-14) was developed and 
evaluated for its in vitro binding properties at the human histamine H3 receptor (hH3R). The 
novel ligands were investigated for their in vivo protective effects in different seizure models 
in male adult rats. Among the H3R ligands (3-14) tested, ligand 14 showed significant and 
dose-dependent reduction in the duration of tonic hind limb extension in maximal electroshock 
(MES)-induced seizure model subsequent to acute systemic administration (5, 10, and 20 mg/kg, 
intraperitoneally), whereas ligands 4, 6, and 7 without appreciable protection in MES model were 
most promising in pentylenetetrazole (PTZ) model. Moreover, the protective effect observed 
for ligand 14 in MES model was lower than that observed for the reference drug phenytoin 
and was entirely abrogated when rats were co-administered with the brain-penetrant H1R 
antagonist pyrilamine (PYR) but not the brain-penetrant H2R antagonist zolantidine (ZOL), 
demonstrating that histaminergic neurotransmission by activation of postsynaptically located 
H1Rs seems to be involved in the protective action. On the contrary, PYR and ZOL failed to 
abrogate the full protection provided by 4 in PTZ model and the moderate protective effect by 
14 in strychnine (STR) model. Moreover, the experimental and in silico estimation of proper­
ties such as metabolism was performed for five selected test compounds. Also, lipophilicity 
using planar reversed-phase thin-layer chromatography method was included for better under­
standing of the molecular properties of the tested compounds. Additionally, the absorption, 
distribution, metabolism, and elimination and toxicity parameters were evaluated for the most 
promising compounds 2, 4, 6, 7, and 14 utilizing in vitro methods. These interesting results 
highlight the potential of H3R ligands as new antiepileptic drugs or as adjuvants to available 
epilepsy medications.
Keywords: histamine H3 receptors, antagonists, anticonvulsant, _R-(a)-methyl-histamine, 
pyrilamine, zolantidine
Introduction
Epilepsy is a group of disorders characterized in common by high predisposition 
to recurrent seizures.1 Etiology can be due to genetic, congenital, and metabolic 
factors or secondary to stroke, trauma, tumors, drugs, alcohol, or medications.1 
Mechanistically, these causes alter intrinsic (eg, pumps, ion channels, transporters) 
activity, modify synaptic transmission, or induce “re-wiring” of neurons, resulting 
in reduced seizure threshold, ie, epileptogenesis.1 Currently existing antiepileptic 
drugs (AEDs) could not help all epileptic patients as practically 30% of them are not 
responding to current therapy. In addition, as long life medication is necessary, the 
search for new and more effective AEDs with enhanced safety profile is a laudable
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therapeutic goal. Up to date, previous research studies 
showed that brain histamine and seizure pathophysiology 
are strongly associated.2,3 Hence, histamine itself is consid­
ered as an endogenous anticonvulsant,2 whereas histamine 
H1 receptor (H1R) antagonists have, in earlier studies, been 
found to induce convulsions.4,5 In addition, in previous 
preclinical studies, inhibition of A-methyltransferase, the 
histamine-metabolizing enzyme in the central nervous 
system (CNS), by metoprine was found to increase brain 
histamine content and to reduce seizure susceptibility.6-9 
Conversely, inhibition of histidine decarboxylase (HDC), 
the histamine-synthesizing enzyme in the CNS, by alpha- 
fluoromethylhistidine has been found to diminish histamine 
synthesis and consequently to increase seizure activity in 
experimental animal models.10 Similarly, HDC knock-out 
mice were more prone to seizures as compared to wild-type 
mice.11 Interestingly, in a recent study, lamotrigine-resistant 
kindled model of epilepsy in mice exhibited reduced level 
of brain histamine, suggesting a role of this neurotransmitter 
in resistance development to the currently available AEDs.12 
Clinically, children with febrile seizures had lower cerebro­
spinal fluid histamine than those with fever but no convul­
sions, suggesting the antiseizure effect of histamine.13,14 
In addition, it has been found that H 1R antagonists increased 
the incidence of seizures in children.4 Moreover, abnormal 
levels of H1Rs around the epileptic focus in complex 
partial seizures were noticed in human positron emission 
tomography studies.15 Furthermore, research during the last 
2 years has provided more information concerning anticon­
vulsant activities of histamine H3R (hH3R) antagonists/ 
inverse agonists investigated in a variety of animal epilepsy 
models.16 Accordingly, both imidazole17 and non-imidazole 
hH3R18-20 ligands provided some protective effects in the
maximal electroshock (MES)-induced seizure in Wistar rats. 
Among a number of active H3R antagonists/inverse agonists 
achieved in both academia and industry, so far only one H3R 
antagonist, namely, pitolisant (1) (PIT; Bioprojet Biotech; 
Figure 1), successfully completed Phase III of clinical trials, 
with positive outcomes in narcolepsy and daytime excessive 
sleepiness in patients with Parkinson’s disease, and is under 
evaluation as an orphan drug (Wakix®; pitolisant hydrochlo­
ride) by Bioprojet Pharma.21-23 Also, a clinical utility of PIT 
was similarly tested in early Phase II studies involving human 
photosensitivity model.24 Accordingly, PIT tested in doses 
of 20, 40, and 60 mg/kg significantly provided a suppressive 
effect in 64% of investigated patients.24 Moreover, in search 
for potent hH3R antagonists/inverse agonists, our research 
group recently succeeded in developing a novel series of H3R 
antagonists/inverse agonists belonging to the non-imidazole 
class and of high antagonist affinities for human hH3Rs.19,25 
Encouraged by the aforementioned results in experimental 
and clinical studies, we decided to investigate selected H3R 
antagonists in MES-, pentylenetetrazole (PTZ)-, and strych­
nine (STR)-induced seizure models in rats.19,25 The results 
observed showed that few of these antagonists provided 
promising anticonvulsant activity, among which was the H3R 
antagonist DL-77 (2) that significantly and dose-dependently 
(5, 10, and 15 mg/kg, intraperitoneally [i.p.]) reduced MES- 
induced seizure duration with protective action comparable 
to that of the reference drug phenytoin (PHT) (Figure 1).19 
Encouraged by these results in experimental epilepsy models, 
and as a continuation of our research, this study investigated 
A-alkyl-substituted (homo)piperidine ether derivatives (3-14) 
(Scheme 1). As lead structures for the introduced modifica­
tions, the drug candidate PIT (1, Wakix) and DL-77 (2) 
have been chosen. Accordingly, the structural modifications
H,C CH,






ED50a =1.5 mg/kg, p.o: 
pK.(hH3R)b =7.943; pK.(hH4R)= =<5; 
pK  (hH1R)d =5.94
ED50a =2.1±0.2 mg/kg, po; 
pK(hH3R)b =8.08; pK.(hH4R)= =4.31; 
pK. (hH1R)d =6.18
F igure  1 Chemical structures, in vitro affinities, and in vivo potencies of previously described H3R ligands PIT (1, Wakix®)22 and DL-77 (2).19,30,72
N o tes: aCentral histamine H3R assay in vivo after po administration to  mice, n=3.30,59-62 b[l25i]iodoproxyfan binding assay at human H3R stably expressed in C H O -K i cells, 
n_3.3o,63,64 c[3H]Histamine binding assay performed with cell membrane preparation of Sf9 cells transiently expressing the human histamine H4R and co-expressed with G ai2 
and GP iy2 subunits, n=3.31,65-67 d[3H]Pyrilamine binding assay performed with cell membrane preparation of C H O -hH  i R cells stably expressing the human H i R, n=3.68-70 
A b brev ia tions: H3R, H3 receptor; PiT, pitolisant; p.o., peroral.
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included the introduction of different cycloalkylamine 
moieties in the basic part of target ligands, ascending alkyl 
chain length (five to six methylene groups), and variable posi­
tion of methyl at the basic piperidine ring (3-CH3 or 4-CH3). 
The general structures of final ligands 3-14 are presented in 
Scheme 1. In addition, in vitro pharmacological evaluation 
of ligands 3-14 included hH3R affinity in a binding assay 
(human embryonic kidney (HEK)-293 cells) and in cAMP 
accumulation assay at HEK-293 cells. Moreover, the novel 
series (3-14) has been examined for its anticonvulsant activ­
ity in MES-, PTZ-, and STR-induced seizure models in adult 
rats. Furthermore and as absorption, distribution, metabolism, 
and elimination (ADME) are very important properties of 
ligands, in vitro studies are often applied at the earlier stages 
of drug discovery. Therefore, the metabolic stability and 
safety tests of five ligands with the most promising anticon­
vulsive effect was evaluated. Furthermore, lipophilicity using 
planar reversed-phase thin-layer chromatography (RP-TLC) 
method was also included for better understanding of the 
molecular properties of the compounds.
Materials and methods
In vitro pharmacology
Antagonist binding to  human hH3R
The displacement binding assay was carried out as described 
by Kottke et al.26 In summary, frozen crude membrane 
preparations of HEK-293 cells stably expressing the full- 
length recombinant hH3R were thawed, homogenized, 
incubated for 90 min at 25°C, and shook at 250 rpm with 
[3H]A“-methylhistamine ([3H]A“-MeHA; 2 nM), and seven 
different concentrations of the test compounds, namely,
0.01 mM, 0.1, 1, 10, and 100 nM, and 1 and 10 |J.M, in a final 
assay volume of 200 |J.L per well were used. As described 
in previous publications,17-19,25,27’28 the antagonist affinity for 
human hH3Rs was tested utilizing radioligand binding assays
and HEK-293 cell membrane preparations. The competi­
tion binding experiments were conducted on membranes 
(20-25 |J.g/well in a final volume of 0.2 mL binding buffer) 
that were incubated with [3H]A“-MeHA (2 nM; 85 Ci/mmol) 
and a variety of concentrations range of the respective test 
ligand. For each compound, assays were conducted at least 
in triplicates with seven appropriate concentrations in the 
range of 0.01 nM to 10 |J.M of the respective test compound, 
and the produced non-specific binding was measured in 
the presence of unlabeled PIT (10 pM). Accordingly, the 
maximal binding concentration (B ) was determined to be
0.89 pmol/mg and the Kd value of [3H]M“-MeHA was found 
to be 2.98 nmol/L (pKd =8.53±0.01) in saturation binding 
experiments. Moreover, filtration through GF/B filters pre­
treated with 0.3% m/v polyethyleneimine using an Inotech 
cell harvester was utilized to separate the bound radioligand 
from free radioligand. Accordingly, unbound radioligand 
was removed from the mixture by three washing cycles with
0.3 mL/well of ice-cold 50 mM Tris-HCl buffer, pH 7.4, 
containing 120 mM NaCl. The filters were saturated in a 
sample bag with 9 mL scintillator liquid (Betaplate Scint; 
PerkinElmer, Germany) and counted using a PerkinElmer 
MicroBeta Trilux scintillation counter. Consequently, the 
analysis of competition binding data was conducted by the 
software GraphPad Prism 3.02 using non-linear least squares 
fit. K  values were calculated from the IC50 values according 
to the Cheng-Prusoff equation.29
In vivo pharmacology
Animals
Inbred male Wistar rats (Central Animal Facility of the 
UAE University) of body weight 180-220 g were used for 
this study. The animals were retained in an air-conditioned 
animal facility room with controlled temperature (24°C±2°C) 
and humidity (55%±15%) under a 12-h light/dark cycle.
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The animals were allowed free access to food and water. 
The experiments of this study were carried out between 9 and 
12 h, and all procedures were performed according to the 
guidelines of the European Communities Council Directive 
of November 24, 1986 (86/609/EEC) and were previously 
approved for epilepsy study by the College of Medicine and 
Health Sciences, United Arab Emirates University (Institu­
tional Animal Ethics Committee, approval number; A9-14).
Drugs
H1R antagonist pyrilamine (PYR, 10 mg/kg, i.p.), H2R 
antagonist (zolantidine [ZOL], 10 mg/kg, i.p.), PTZ 
(60 mg/kg, i.p.), STR (3.5 mg/kg, i.p.), PHT, and valproic 
acid (VPA) were purchased from Sigma-Aldrich (St Louis, 
MO, USA). The H3R ligands: 1-(5-(4-propylphenoxy) 
pentyl)piperidine hydrogen oxalate (3) -  unpublished; 
3-methyl-1 -(5-(4-propylphenoxy)pentyl)piperidine hydrogen 
oxalate (4) -  unpublished; 4-methyl-1-(5-(4-propylphenoxy) 
pentyl)piperidine hydrogen oxalate (5) -  unpublished; 
1-(5-(biphenyl-4-yloxy)pentyl)-3-methylpiperidine hydro­
gen oxalate (6) -  unpublished; 1-(5-(4-propylphenoxy) 
pentyl)azepane hydrogen oxalate (7) -  unpublished; 1-(5- 
(2,3-dihydro-1#-inden-5-yloxy)pentyl)azepane hydrogen 
oxalate (8) -  unpublished; 1-(6-(4-ethylphenoxy)hexyl)- 
3-methylpiperidine hydrogen oxalate (9) -  unpublished; 
3-methyl-1-(6-(4-propylphenoxy)hexyl)piperidine hydrogen 
oxalate (10) -  unpublished; 1-(4-(6-(3-methylpiperidin- 
1-yl)hexyloxy)phenyl)propan-1-one hydrogen oxalate 
(11) -  unpublished; 1-(6-(biphenyl-4-yloxy)hexyl)-3-meth- 
ylpiperidine hydrogen oxalate (12) -  unpublished; 3-methyl- 
1 -(6-(naphthalen-1 -yloxy)hexyl)piperidine hydrogen oxalate 
(13) -  unpublished; 1-(6-(naphthalen-1 -yloxy)hexyl)azepane 
hydrogen oxalate (14) -  unpublished; PIT (1); and DL 77 (2) 
were designed and synthesized in the Department of Technol­
ogy and Biotechnology of Drugs (Krakow, Poland) according 
to previously described procedures30’31 (Figure 1; Table 1). 
Liquid chromatography-mass spectrometry was conducted 
on a system that involves a Waters Acquity UPLC, attached 
to a Waters TQD mass spectrometer. The retention times (tR) 
are provided in minutes, and RP-TLC data were acquired with 
Merck Silica gel 60 RP-18 F254S glass plates by means of 
planar chromatographic CHROMDES chambers. The solu­
tions of test compounds were applied using Hamilton 25 |jL 
syringes. The compounds were detected by means of the 
staining of TLC plates using iodine vapors. Isotonic saline 
solutions of test compounds 3-14, PIT, PHT, VPA, PYR, 
and ZOL were administered i.p. at a volume of 1 mL/kg for 
the in vivo studies. Doses of all test compounds (5, 10, and
Table 1 Affinities of test compounds 3-14 at hH3R stably expressed 
in HEK cells
H 3R  ligand S tructure  K  (h H 3R )a (n M )
1 (PIT) 11.69±2.47b
N o tes: ^ ^ N ^ M e h A  binding assay performed with cell membrane preparation 
of HEK cells stably expressing the human H3R (n=3). bValues published.20 cValues 
published.30
A b brev ia tions: hH3R, histamine H3 receptor; HEK, human embryonic kidney; 
PIT, pitolisant; [3H ]N a-MeHA, [3H ]N a-methylhistamine.
20 mg/kg, i.p.) were expressed in terms of the free base. For 
each test compound, a group of seven rats was used to carry 
out the anticonvulsant study.
MEs-induced seizure
As previously described,17-19,25,27,28 the convulsions were 
induced in rats utilizing a 50-Hz alternating current with
su b m it yo u r m a nus crip t | www.dovepress.com
D ovepress







































































Dovepress Histamine H3R antagonists as potent anticonvulsant drugs
120 mA of intensity. The current was applied through ear 
electrodes for a duration of 1 s, and the protection against the 
spread of MES-induced convulsion was defined as the aboli­
tion of the tonic hind limb extension (THLE) component of 
the convulsion.17,18,25,32 The animals were divided into groups 
of seven rats. In the positive control group, rats were injected 
with PHT at a dose of 10 mg/kg, this being the minimal dose 
of PHT that protected animals against the spread of MES- 
induced seizures without mortality in rats. Animals in the 
experimental groups were administered test ligands at doses 
of 5, 10, or 20 mg/kg, i.p., 30 min before the MES challenge. 
In a further experiment, the most effective dose of ligand 14 
was selected for further analysis. In two separate groups of 
seven rats, the selected dose of 14 was co-administered with 
PYR (10 mg/kg, i.p.) or ZOL (10 mg/kg, i.p.) 5 min apart 
and before challenge to the MES test.
chemically induced seizures
In the current project and according to previously used 
experimental procedures, two chemical agents, namely, PTZ 
and STR, were utilized to induce convulsions.17-19,25,27,28 First, 
different doses of these proconvulsant compounds have been 
examined (in six to eight rats per dose) to define the minimum 
dose that induces convulsions in all treated animals.19,33-37 
This minimal proconvulsant dose was then applied to screen 
potential anticonvulsant activities of the test compounds 
3-14. Consequently, PTZ (60 mg/kg, i.p.) or STR (3.5 mg/kg, 
i.p.) was administered to all experimental test groups (six to 
eight rats per group), ie, saline and treated rats. Saline, VPA 
(100 mg/kg, i.p.),19 PIT (10 mg/kg, i.p.), or tested ligands 3-14 
(10 mg/kg, i.p.) were injected 30 min prior to PTZ (60 mg/kg, 
i.p.) or STR (3.5 mg/kg, i.p.) administration, and rats were 
immediately observed for 30 min (experiment period) for 
any convulsive signs. The convulsion signs were observed, 
and graded scores have been used to assess the severity of 
convulsions according to the following scale: score 0= no 
seizures, score 1= eye or facial twitches, score 2= convulsive 
waves across the body, score 3= myo-clonic jerks or rearing, 
score 4= turn over on to one side position, and score 5= turn 
over on to back position, generalized tonic-clonic seizures, or 
die during the experiment period. The animals were divided 
into groups of seven rats. In the positive control group, rats 
were injected with VPA at a dose of 100 mg/kg, this being 
the minimal dose of VPA that protected animals against 
PTZ-induced seizures without mortality in rats. Animals in 
the experimental groups were administered test compounds 
at doses of 5, 10, or 20 mg/kg, i.p., 30 min before the PTZ or 
STR treatment. In a further experiment, the most protective
dose of test ligand 4 was selected for further analysis. In two 
separate groups (seven animals each), the selected dose of 
4 was co-administered with PYR (10 mg/kg, i.p.) or ZOL 
(10 mg/kg, i.p.) 5 min apart and prior to PTZ treatment -  or 
in case of ligand 14 STR treatment. Notably, the current 
treatment used in the MES study was the one that produced 
convulsions in 100% of rats without mortality. Likewise, the 
dose of PTZ and STR used in this study formed convulsions 
in 100% of animals without mortality.
statistical analysis
For statistical comparisons, the software package SPSS 20.0 
(IBM Middle East, Dubai, UAE) was used. All data were 
expressed as the mean ± standard error of the mean. The 
effects of test compounds on epilepsy were analyzed using 
a mixed repeated-measures two-way analysis of variance 
(ANOVA) with Treatment (vehicle or test compound) and 
Dose (test compound) as the between-subjects factor. The 
effect of selected test compound in combination with PYR 
and ZOL on anticonvulsant effect was analyzed using one­
way ANOVA with Treatment as the between-subject factor. 
In case of a significant main effect, post hoc comparisons 
were performed with Bonferroni’s test. The criterion for 
statistical significance was set at a P-value of <0.05.
Lipophilicity studies
Lipophilicity, by means of RM0 values, was assessed by means 
of RP-TLC planar method, and a methanol/acetic acid/water 
(with constant, 10% acid concentration) solvent mixture was 
used as a mobile phase. The organic solvent concentration 
varied from 85% to 55%, by 5% for each step. The composi­
tions of the mobile phase and concentrations were selected 
experimentally. For each concentration, 10 |uL of ligands 
methanol solution in 1 mg/mL concentration was used in the 
test, and the saturation of planar chromatographic chambers was 
achieved with suitable mixture for 45 min, followed by 15 min 
saturation together with the plate. Evaluation of glass plates 
was carried out at a distance of 90 mm, the glass plates were 
dried, and the resulting spots were envisioned utilizing iodine 
fumes. For each of the test ligands and considering the base of 
Rf values, the RM values were determined. RM0 values were read 
from RM/methanol concentration charts, after extrapolation to 
zero methanol concentration using in-house script.
selected ADME-Tox parameter studies
Metabolic stability
Commercial, pooled, human (adult male and female) liver 
microsomes (HLMs) were purchased from Sigma-Aldrich.
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The biotransformations were conducted using 1 mg/mL 
of HLMs in 200 |jL of reaction buffer containing 0.1 M 
Tris-HCl (pH 7.4) and the respective test compound (H3R 
ligand) with a final volume of 50 |J.M. The reaction mixture 
was preincubated at 37°C for 5 min, and then, the reaction 
was commenced by adding 50 |jL of NADPH Regenera­
tion System (Promega, Madison, WI, USA). The reaction 
was ended after 120 min by the addition of cold methanol 
(200 |jL). The mixture was next centrifuged at 14,000 rpm for 
15 min, and the ultra-performance liquid chromatography- 
mass spectrometry (UPLC/MS) analysis of the supernatant 
was performed. Mass spectra were recorded on UPLC/ 
MS system that consisted of a Waters Acquity UPLC 
(Waters, Milford, CT, USA), joined to a Waters TQD mass 
spectrometer (electrospray ionization mode ESI-tandem 
quadrupole). The in silico investigation was achieved by 
MetaSite 4.1.1 provided by Molecular Discovery Ltd, and the 
probability sites with the highest metabolism were analyzed 
during this study by liver computational model.
Influence on recombinant human cytochromes P450 
(CYPs) 3A4 and 2D6
The luminescent CYP3A4 P450-Glo™ and CYP2D6 P450- 
Glo™ assays and protocols were provided by Promega.38 
The reference drugs ketoconazole (KE) and quinidine (QD) 
were obtained from Sigma-Aldrich. The enzymatic reactions 
were accomplished in white polystyrene, flat-bottom Nunc™ 
MicroWell™ 96-Well Microplates (Thermo Fisher Scientific, 
Waltham, MA, USA). The luminescence signal was mea­
sured by using a microplate reader in luminescence mode 
(EnSpire; PerkinElmer, Waltham, MA, USA). The IC50 value 
of KE was determined and calculated as reported previously.39 
The IC50 value of the reference drug QD was determined 
according to the manufacturer’s recommendations at the final 
concentrations of 0.1-100 nM. The final concentrations of 
test ligands were comparable for both CYP3A4 and CYP2D6 
assays and were in the range of 0.025-25 |J.M.
Safety profile 
Antiproliferative activity
Human embryonic kidney HEK-293 cell line (ATCC CRL1573) 
was kindly provided by Prof Dr Christa Müller (Pharmaceutical 
Institute, Pharmaceutical Chemistry I, University of Bonn). 
As described previously, the cell lines were cultured in 
Dulbecco’s Modified Eagle’s Medium (Gibco) with 10% 
fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL 
penicillin at 37°C in an atmosphere containing 5% of CO2.40 
The HEK-293 cells were seeded in 96-well plates at a
concentration of 1x104 cells/well in 200 |jL culture medium 
and cultured for 24 h to reach 60% confluence. Next, the 
25 mM stock solutions of H3R ligands in dimethyl sulfoxide 
(DMSO) were diluted into fresh growth medium and added 
into the microplates at the final concentrations of 0.1-250 |J.M 
(DMSO concentration did not exceed 1%). After 48 h of 
incubation, 20 |J.L of EZ4U labeling mixture (Biomedica) was 
added to each well, and the cells were incubated under the 
same conditions for 5 h. The absorbance of the samples was 
measured using a microplate reader (PerkinElmer) at 492 nm. 
The IC50 value of the reference drug doxorubicin (DX) was 
determined and calculated as reported previously.40 GraphPad 
Prism™ software (version 5.01, San Diego, CA, USA) was 
used to calculate IC50 value of H3R ligands.
Genotoxic activity (Ames test)
Ames microplate fluctuation protocol (MPF) assay was per­
formed as described previously with Salmonella typhimurium 
strain TA98, enabling the detection of frameshift mutations.41 
Bacterial strain as well as exposure and indicator medium 
were purchased from Xenometrix AG (Allschwil, Switzer­
land). The mutagenic potential of test ligands was assessed 
by incubation of bacteria, incapable of producing histidine, 
with particular concentration of compound for 90 min in 
exposure medium, containing limited amount of histidine. 
The manifestation of reversion events to histidine prototro­
phy was detected as a growth of bacteria in the indicator 
medium without histidine after 48 h of incubation in room 
temperature, and the growth of bacteria in 384-well plates 
was projected by a color change in the medium from violet 
to yellow upon addition of pH indicator dye. The respective 
test compound was classified as mutagenic depending on 
the ratio of positive wells and the solvent control baseline 
(FIB, >2-fold). FIB was defined as the mean number of 
positive wells in the negative control sample, increased by 
one standard deviation. The reference mutagen (0.5 pM) 
nonyl-4-hydroxyquinoline-N-oxide (NQNO) was used as a 
positive control in performed experiments.
Results
Pharmacology
In v itro  antagonist affinities at hHIR, hH3R, 
and hH4Rs
The novel compounds were first tested for their antagonist 
H3R affinity obtained by [3H]A“-MeHA binding assay on 
HEK-293 cell membrane preparation stably expressing 
hH3R. The observed antagonist affinities for hH3Rs are 
summarized in Table 1.
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In vivo seizure models
Protective activity of H3R ligands 3-14 in MES-induced 
seizure model
The protective activities of acute systemic administration 
of H3R ligands 3-14 on MES-induced seizures in rats were 
investigated (Figure 2A). The results showed that pretreat­
ment with PHT, PIT, and H3R ligands 3-14 (10 mg/kg, i.p.) 
provided a significant protective action against MES-induced 
convulsions as confirmed by applying one-way ANOVA with 
[F(1490) =29.13; P<0.001]. Among the H3R ligands tested, 
compounds 13 and 14 at a dose of 10 mg/kg significantly 
exhibited the most promising protective effects against 
MES-induced convulsion in rats when compared with the 
saline-treated group with [F ) =73.13 and F  =76.68, 
respectively, all P<0.001] (Figure 2A). Moreover, the results 
show that ligands 13 and 14 provided comparable protec­
tion compared to PIT with [F^ 12) =2.21 and F(112) =3.43, 
respectively, all P>0.05], whereas the provided protection 
observed was significantly lower than that of the reference 
drug PHT with [F^ 12) =26.65 and F(112) =20.19, respectively, 
all P<0.001].
[F =9.82, P<0.005]. In addition, substantial intensifi­
cations of protective activities were observed upon acute 
systemic injection with 10 and 20 mg/kg of H3R ligand 14 
when compared with 5 mg/kg of the same compound 
with [F(112) =7.52, P<0.05] and [F(112) =8.25, P<0.001], 
respectively (Figure 2B).
Effect of PYR and ZOL pretreatment on the protective 
activity provided by H3R ligand 14 on MES-induced 
seizures
The reversal of protection provided by H3R ligand 14 was 
tested by co-administration with CNS-penetrant hH1R 
antagonist PYR (10 mg/kg, i.p.) or the CNS-penetrant 
ZOL (10 mg/kg, i.p.) 30 min before MES challenge with 
[F =0.22; P=0.645, for the comparison of saline-saline vs 
14+PYR] and [F^ 12) =0.88; P=0.3678, for the comparison of 
saline-14 vs 14+ZOL], respectively (Figure 2B). Moreover, 
PYR and ZOL when administered alone did not affect MES- 
induced seizures with (P=0.883 saline-saline vs saline-PYR) 
and (P=0.759 saline-saline vs saline-ZOL), respectively 
(Figure 2B).
Dose-dependent protective activity of H3R ligand 14 
in MES-induced seizure model
The results show that animals pretreated with 5 mg/kg of 
H3R ligand 14 were significantly protected against con­
vulsions when compared with the saline-treated group
Protective activities of H3R ligands 3-14 pretreatment 
on PTZ-induced convulsions
The effects of H3R ligands 3-14 (10 mg/kg, i.p.) and PIT 
were assessed and compared with the protective effect of 
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Figure 2 Protective effect of acute systemic injection of H3R ligands 3 -1 4  on MES-induced convulsions in rats.
Notes: (A ) The figure shows the protective effects of PHT (10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), and test compounds 3 -1 4  (10 mg/kg, i.p.) on the duration of THLE induced in the 
MES model in rats. Values are mean ±  SEM (n=7). *P<0.005 vs the saline-treated group. **P <0.00l (B) 1: Dose-dependent effect of H3R ligand 14 (5, 10, and 20 mg/kg, i.p.) on 
duration of THLE induced in the MES model in rats; 2: Effect of PYR (10 mg/kg, i.p.) and ZO L (10 mg/kg, i.p.) pretreatment on the protection provided by H3R 14 (10 mg/kg, i.p.) 
against MES-induced convulsions. Each value represents mean ±  SEM (n=7). *P<0.05 vs (saline)-treated group. **P <0.00l vs (saline)-treated group. #P<0.05 vs (5 mg)-treated 
group.
A b brev ia tions: H3R, H3 receptor; MES, maximal electroshock; PHT, phenytoin; PIT, pitolisant; THLE, tonic hind limb extension; PYR, pyrilamine; ZO L, zolantidine; 
SEM, standard error of the mean; SAL, saline.
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(Figure 3A). The results showed that ligands 4, 6, and 7 
delivered significant protective activities when compared 
to the saline-treated group after 10, 20, and 30 min of 
observation [all P<0.05] (Figure 3A). However, PIT did 
not show protective activity in the PTZ model after 10, 
20, and 30 min [F(112) =0.03, 0.01, and 0.50, respectively, 
all NS]. Notably, VPA (100 mg/kg) provided significant 
protection when compared with saline-treated group after 
10, 20, and 30 min with [F =101.4, 44.74, and 16.8; 
all P<0.05].
Dose-dependent protective activity of H3R ligands 
4 and 6 on PTZ-induced convulsions
One-way ANOVA showed that pretreatment with reference 
AED VPA and ligands 4 and 6 (5, 10, and 20 mg/kg, i.p.) 
exerted a significant protective action against PTZ-induced 
convulsions with [F(748) =25.63; P<0.001], [F(748) =13.47; 
P<0 .001], and [F(7,48) = 8.10; P <0.001] after 10, 20, 
and 30 min of observation, respectively (Figure 3B). In 
addition, the results showed that significant and full pro­
tection was provided at 10, 20, and 30 min after acute 
systemic administration with 10 mg/kg of ligands 4 and 6 
(P<0.001) (Figure 3B). Moreover, the results showed that 
PYR and ZOL when administered alone failed to reverse 
the protection provided by H3R ligand 4 (10 mg/kg, i.p.) 
(Figure 3B).
Protective activities of H3R ligands 3-14 pretreatment 
on STR-induced convulsions
In STR-induced seizure model, only H3R ligand 2 pro­
vided significant protective activity when compared to the 
saline-treated group after 10, 20, and 30 min of observa­
tion [P<0.05] (Figure 4A). Similar to the reference drug 
VPA, ligands 13 and 14 exhibited significant protective 
effect as compared with the saline-treated group after 10, 
20, and 30 min [all P<0.001] (Figure 4A). Moreover, PIT 
(10 mg/kg, i.p.) did not provide protective action after 10, 
20, and 30 min [F(112) =0, 3.32, and 3.50; all NS], respec­
tively. However, the reference AED VPA (300 mg/kg, i.p.) 
provided significant protection when compared with saline- 
treated group after 10, 20, and 30 min with [F =41.82;
P<0.05], [F(U2) =144.15; P<0.05], and [F(U2) =81.82; 
P <0.05], respectively.
Dose-dependent protective activity of H3R ligand 14 
on STR-induced convulsions
The results show that acute systemic administration with 
reference AED VPA and ligand 14 (5, 10, and 20 mg/kg,
i.p.) exerted a significant protective effect against STR- 
induced convulsions as confirmed with one-way ANOVA 
with [F(430) =33.27; P<0.001], [F(430) =57.46; P<0.001], and 
[F(430) =80.07; P<0.001] for 10, 20, and 30 min observations, 
respectively (Figure 4B). In addition, the results revealed that
PTZ (60 mg/kg, i.p.)
] 10 min 20 min I I 30 min
4 6 4 (B ) SAL
PTZ (60 mg/kg, i.p.)
Figure 3 Protective effect of H3R ligands 3 -1 4  pretreatment on PTZ-induced convulsions in rats.
Notes: (A ) VPA (100 mg/kg, i.p.), PIT (10 mg/kg, i.p.), and compounds 3 -1 4  (10 mg/kg, i.p.) were injected 30 min before PTZ (60 mg/kg, i.p.) treatments. Effects shown are 
expressed as score of seizures after 10, 20, and 30 min of PTZ injection. Data are expressed as the mean ±  SEM (n=7). *P<0 .05 vs the (PTZ-saline)-treated group. #Full 
protection. (B) Dose-dependent effect of H3R ligands 4 and 6 (A, B, and C in a dose of 5, 10, and 20 mg/kg, i.p. respectively) on the convulsion score induced in the PTZ 
model in rats. Effect of PYR (10 mg/kg, i.p.) and Z O L  (10 mg/kg) pretreatment on the protection provided by H3R ligand 4 (10 mg/kg, i.p.) against PTZ-induced convulsions. 
Each value represents mean ±  SEM (n=7). *P<0.05 vs (PTZ-saline)-treated group. #Full protection.
A b brev ia tions: H3R, H3 receptor; PTZ, pentylenetetrazole; VPA, valproic acid; PIT, pitolisant; SEM, standard error of the mean; PYR, pyrilamine; ZO L, zolantidine.
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SAL 14 14 (B) SAL
STR (3.5 m g/kg, i.p.)
10 min 20 min H 30 min
Figure  4 Protective effect of H3R ligands 3 -1 4  pretreatment on STR-induced convulsions in rats.
N o tes : (A ) VPA (300 mg/kg, i.p.), PIT (10 mg/kg, i.p.), and compounds 3 -1 4  (10 mg/kg, i.p.) were injected 30 min before STR (3.5 mg/kg, i.p.) treatments. Values are 
expressed as the mean ±  SEM (n=7). *P <0 .00 i vs (STR-saline)-treated group. #Full protection. (B) Dose-dependent effect of H3R ligand 14 (A, B, and C in a dose of 5, 
10, and 20 mg/kg, i.p., respectively) on the convulsion score induced in the STR model in rats, and effect of PYR (10 mg/kg, i.p.) and Z O L  (10 mg/kg) pretreatment on the 
protection provided by H3R ligand 14 (10 mg/kg, i.p.) against STR-induced convulsions. Each value represents mean ±  SEM (n=7). *P<0.05 vs (PTZ-saline)-treated group. 
* *P < 0 .0 0 i. #Full protection.
A b brev ia tions: H3R, H3 receptor; STR, strychnine; VPA, valproic acid; PIT, pitolisant; SEM, standard error of the mean; PYR, pyrilamine; ZO L, zolantidine; PTZ, pentyl- 
enetetrazole.
significant and full protective activity was obtained at 30 min 
after administration with only 10 mg/kg of 14 (P<0.001). 
However, lower dose (5 mg/kg, i.p.) and higher dose (20 mg/ 
kg, i.p.) of 14 showed merely moderate protection against 
STR-induced convulsions when compared at 10, 20, and 
30 min to the dose of 10 mg/kg of the same compound [all 
P<0.05]. Similar to the results observed in the PTZ model, 
PYR and ZOL failed, also, to reverse the protection provided 
by H3R ligand 14 (10 mg/kg, i.p.) in STR-induced convul­
sion model (Figure 4B).
Discussion
In vitro hH3R antagonist affinity
All compounds in their hydrogen oxalate forms were evalu­
ated in radioligand displacement binding assays for affinity at 
human recombinant hH3R (hH3R) stably expressed in human 
embryonic kidney (HEK-293) cells as described by Kottke 
et al.26 The radioligand [3H ]^“-MeHA was used as a com­
petitor. Pharmacological results are assembled in Table 1. 
All tested compounds showed affinities for hH3R in nanomo­
lar concentration range (K.: 27-156 nM). For the tested group 
of novel H3R ligands, among four different cycloalkylamine 
moieties used (piperidine, 3-methylpiperidine, 4-methylpipe- 
ridine, homopiperidine), it is obvious that 3-methylpiperidine 
is the most preferable basic moiety for hH3R binding 
pocket. Interestingly, 3-methylpiperidine derivative 6 with
hH3R K. values of 27.3±15 with pentyl alkyl spacer showed 
higher antagonist affinity in comparison to their correspond­
ing derivatives with hexyl alkyl chain (eg, 10 and 12 with 
hH3R K. values of 85.9±24.8 and 146.5±65.3 nM, respec­
tively) (Table 1). On the other hand, for 4-phenylsubstituted 
compound 6, having the alkyl chain of pentyl resulted in 
the increment of hH3R antagonist affinity (6 vs 12; hH3R 
K  =27.3±15.1 vs K  =146±653 nM, respectively), whereas in 
the 4-substituted propylphenyl derivatives a replacement of 
3-methylpiperidine with homopiperidine resulted in high dec­
rement of the affinity (eg, 4 vs 7; hH3R K  =38.4±13.2 nM vs 
hH3R K  =56.3±1.2 nM, respectively) (Table 1). Noticeably, 
elongation of alkyl spacer from propyl in the lead compound 
2 (PIT) to pentyl (eg, in compound 3) or hexyl (eg, in com­
pound 10) resulted in a dramatic decrease of antagonist affin­
ity for hH3Rs (2 vs 3 vs 10; hH3R K. =8.4±1.3 nM vs hH3R 
K  =48±11.5 nM vs hH3R K. =85.9±24.8 nM, respectively). 
Compound 6 (hH3R K  =27.3±15.1 nM) showed in fact 
the highest affinity toward hH3R in the current tested group 
of compounds. However, compound 12, being direct struc­
tural homolog of 6, showed radical loss of affinity (6 vs 12; 
hH3R K  =27.3±15.1 nM vs 146.5±65.3 nM, respectively), 
demonstrating clearly that the length of alkyl spacer and 
consequently the position of ether moiety play a crucial role 
in receptor-ligand interactions for this series of derivatives. 
In summary, compounds incorporating a pentyl alkyl spacer
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with 3-methylpiperidine and a phenyl substituent in the 
para-position of the phenyl ring seem to confer higher affin­
ity than those of 4-substituted methylpiperidine derivative 
(being 6 with hH3R K  value of 27.3+15.1 nM). In conclusion 
and among the examples discussed so far in the present small 
series, phenyl substitution in the 4-position of phenyl moiety 
appears to be the most advantageous position to provide the 
respective ligand with high affinity for the binding pocket 
of hH3R.
In vivo anticonvulsant activity
In the MES model and as compared with standard H3R 
antagonist PIT (10 mg/kg, i.p.), the saline-treated group, and 
the H3R antagonist 14-treated group at a dose of 5 mg/kg, the 
results showed that H3R antagonists 13 and 14 provided the 
most promising protection after systemic injection with 
10 and 20 mg/kg, i.p. (Figure 2A). Consequently, the results 
indicated a dose-dependent relationship of the observed pro­
tection and the presence of a ceiling for H3R antagonist 14 
in MES-induced convulsions. Particularly, the protection 
exhibited by H3R antagonist 14 (10 or 20 mg/kg, i.p.) was 
similar to that observed in the group pretreated with the 
reference AED PHT (10 mg/kg, i.p.) (Figure 2A). The latter 
results are in agreement with recent studies that described 
the dose-dependent anticonvulsant effect of H3R antago­
nists in MES-induced seizure models and, also, for PIT in 
a photosensitivity seizure model in adult patients.17-19,24,25 
A further experiment in this study indicated that the protec­
tion observed for H3R ligand 14 was abrogated when rats 
were co-administered with the CNS-penetrant hH1R antago­
nist PYR (10 mg/kg, i.p.) but not with the CNS-penetrant 
hH2R antagonist ZOL (10 mg/kg, i.p.) in the MES model 
(Figure 2B). Interestingly, PYR (10 mg/kg) and ZOL (10 mg/ 
kg) administered alone did not show either a protective or an 
epileptogenic effect in rats challenged by the MES-induced 
convulsion. These findings propose that the protection of 
H3R antagonist 14 in the MES-induced convulsion is facili­
tated, at least in part, through H3R blockade and interactions 
of released histamine with postsynaptically located hH1Rs. 
The latter observation is in agreement with the previously 
observed protective effects for H3R antagonists.6,17,19,25 
Hereafter, H3Rs are auto-receptors located on presynaptic 
histaminergic terminal neurons and inhibit the synthesis and 
the release of histamine.42 Consequently, antagonizing these 
H3Rs by compound 14 would result in an increased neuronal 
release of brain histamine that provides the protective action 
observed in the MES model. Particularly, comparable effects 
of imidazole- and non-imidazole-based H3R ligands have
been described previously to be reversed either by H3R 
agonists or by CNS-penetrant H1R antagonists, but not by 
CNS-penetrant H2R antagonists, representing an interac­
tion of the H3R antagonism-released histamine with H1Rs 
on postsynaptic neurons.6,17,19,25,43 However, a functional 
in vivo bioassay, eg, drinking bioassay, is essentially required 
to comprehend the in vivo H3R antagonist potency of the 
described novel ligands, eg, ligand 14 to further confirm 
their capability to exert an in vivo antagonist effect through 
interaction with H3Rs. On the other hand and while VPA 
(100 mg/kg, i.p.) provided full protection in the PTZ-induced 
convulsion model, acute systemic administration of H3R 
antagonists 13 and 14 (10 mg/kg, i.p.) offered moderate 
protective activity (Figure 3A). Notably, PIT used as the 
standard H3R antagonist (10 mg/kg, i.p.) did not exhibit 
any protective effect in chemically induced convulsions. 
Moreover, H3R ligands 4 (10 mg/kg, i.p.), 6 (10 mg/kg,
i.p.), and 7 without any considerable protection in the MES 
model provided full protective activity in the PTZ-induced 
convulsion model. Furthermore, lower doses (5 mg/kg, i.p.) 
or higher doses (20 mg/kg, i.p.) of both ligands (4 and 6) 
failed to demonstrate a dose-dependent protection in the PTZ 
model (Figure 3A). In an additional experiment, the protec­
tive effect of H3R ligand 4 (10 mg/kg, i.p.) was not reversed 
when rats were pretreated with PYR (10 mg/kg, i.p.) or ZOL 
(10 mg/kg, i.p.) before PTZ challenge (Figure 3B). These 
findings suggest that the protective effects observed for H3R 
ligand 4 in the PTZ model are not mediated through hista- 
minergic neurotransmission. The latter finding could, also, be 
due to differences in the trigger or the mechanism of seizures 
and the type of seizures each model represents. Accordingly, 
MES is a model of generalized tonic-clonic seizures,44 while 
PTZ (60 mg/kg, i.p.) induces generalized myoclonic and/or 
tonic-clonic convulsions.45 Moreover, electrically induced 
seizures result from stimulation of all neuronal pathways 
where the insult only lasts for short time (1 s). However, in 
chemically induced convulsions, the trigger remains until 
the elimination of the proconvulsant, eg, PTZ. Furthermore, 
chemical agents have in previous studies been found to affect 
only some neuronal pathways, eg, PTZ provides blockage 
of i-butylbicyclophosphorothionate site at GABAa receptors 
and reduces GABA neurotransmission.44-46 Notably, previous 
studies have, also, shown that other neurotransmitters such as 
GABA could be the additional player(s) in the mechanism of 
the protection provided in the PTZ-induced animal convul­
sion model. It can, also, be hypothesized that H3R antagonists 
(eg, 4 and 6) could also block histamine H3 heteroreceptors 
that control the release of other neurotransmitters including
su b m it yo u r m a nus crip t | www.dovepress.com
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GABA.47,48 Interestingly in a previous study, the H3R antago­
nist clobenpropit was found to increase GABA release and 
to protect from NMDA-induced excitotoxicity in rat cultured 
cortical neurons.49
In a further experiment and among tested ligands 3-14, 
the results observed showed that acute systemic administra­
tion of H3R antagonists 13 and 14 (10 mg/kg, i.p.) offered 
some appreciable protection in the STR-induced convulsion 
model, whereas the standard AED VPA (300 mg/kg, i.p.) 
exhibited full protection following 10-30 min time obser­
vation (Figure 4A). Moreover, the lower dose (5 mg/kg,
i.p.) and higher dose (20 mg/kg, i.p.) of H3R antagonist 14 
failed to provide a dose-dependent protection against STR 
model (Figure 4B). Furthermore and in similarity to the 
results observed in the PTZ model, additional experiment 
indicated that the protective effect of H3R antagonist 14 
against STR-induced convulsion was not reversed when rats 
were pretreated with 10 mg/kg, i.p., of the CNS-penetrant 
hH1R antagonist PYR or with the CNS-penetrant hH2R 
antagonist ZOL (10 mg/kg, i.p.) 30 min before STR challenge 
(Figure 4B). These findings further comprehend our results 
that the protective effects observed for H3R antagonist 14 
in the PTZ-induced seizure model, considered also a chemi­
cally induced convulsion model, are not mediated through 
histaminergic neurotransmission. Moreover, it is well rec­
ognized that STR functions as a competitive antagonist of 
the inhibitory amino acid glycine. As a result, the failure 
of H3R ligand 14 to provide a dose-dependent protection 
against STR-induced convulsion advocates little or no effect 
on the glycine receptors, since the mechanism underlying 
STR-induced convulsions is thought to be credited to its 
blocking effect on glycine receptors in the brain and in the 
spinal cord.35 Notably, the discrepancy in the anticonvulsant 
effects observed for the described ligands of varied in vitro 
antagonist affinities could also be clarified by the different 
constructs and predictive validities of the MES, PTZ, and 
STR models. Hereafter, the end point in the MES test is 
THLE, which is considered to be a predictive model for 
generalized tonic-clonic seizures, whereas the PTZ or STR 
test is used as a predictor of anticonvulsant ligand activity 
against non-convulsive (absence or myoclonic) seizures. 
It is, also, noteworthy to mention that most marketed AEDs 
were not effective in all convulsion models conducted during 
preclinical drug development. For instance, carbamazepine, 
oxcarbazepine, and PHT were found to be -  and are 
still -  highly effective in the MES-induced convulsion model; 
however, they lack any protective effects against convulsions 
induced by PTZ, STR, or picrotoxin.50,51 On the contrary,
ethosuximide and tiagabine, which provide high protection 
in chemically induced convulsion models, are inactive in 
the MES-induced convulsion model when used at non-toxic 
doses.51 These different preclinical activities were translated 
into the clinical utility of PHT, carbamazepine, and oxcar­
bazepine but not ethosuximide or tiagabine in generalized 
tonic-clonic convulsions.
Lipophilicity evaluation by planar RP-TLc
At the early stage of preclinical research, there is an influ­
ential aim to investigate physicochemical properties of 
novel compounds. Therefore, the lipophilicity of promising 
hH3R ligands was experimentally assessed (expressed by 
RM0 values) applying planar RP-TLC method.52 As a mobile 
phase, ternary solvent mixture -  ethanol/acetic acid/water -  
was used, with constant, 10% acetic acid concentration and 
varying methanol concentration in the range of 50%-85% 
(5% by each step). Tested series of H3R ligands exhibited RM0 
values in the range of 1.43-1.91 as depicted for the observed 
lipophilicity studies data in Table 2. As it was anticipated, 
lipophilic character of the respective derivative increases with 
the elongation of the alkyl chain. In addition, values resulted 
in the similar range for structural analogs, eg, ligands 4 
and 10 as well as 13 and 14, respectively. Comparable 
dependence was observed for 3- and 4-methylpiperidine 
structural isomeric analogs, eg, ligands 4 and 5, and to 
some extent, lower values were observed for homopiperi­
dine derivatives in comparison with their respective 3(4)- 
methylpiperidine analogs (Table 2). However, association 
between lipophilicity and hH3R affinity was not observed for 
the tested series as well as for lipophilicity and anticonvulsant 
activity. With the aim of comparing the theoretical partition 
coefficient parameters (clogP) with practical ones, calcula­
tions using various computer programs, Chem3D, Marvin,
Table 2 Practical (RM0) and theoretical lipophilicity values for the 
series of described compounds
N o R m o M arvin
16.4.18




3 1.461 1.61 4.90791 4.888
4 1.434 1.97 5.22047 5.151
5 1.431 1.89 5.43386 5.287
6 1.572 2.22 5.70061 5.919
7 1.154 2.05 5.24749 5.247
9 1.435 1.97 5.00709 5.307
10 1.479 2.42 5.56006 5.700
11 0.676 1.27 4.20444 4.451
12 1.903 2.66 6.04019 6.240
13 1.881 2.00 5.36708 5.616
14 1.911 2.08 5.39409 5.614
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and QikProp for Schrödinger, were also implemented as 
described previously,53-55 since such obtained theoretical 
values appear to be more representative, considering the 
reality that all the test H3R ligands are present in their salt 
forms as hydrogenoxalates. While most comparable, the ratio 
(theoretical-to-practical) values were obtained using Marvin 
software, the best correlation was obtained using QikProp 
by Schrödinger (R=0.783), (R2=0.613).
Selected ADME-toxicity (Tox) parameter 
study
In the modern drug discovery and development process, 
it is required to evaluate not only the pharmacological 
properties but also the ADME-Tox parameters together 
as early as possible. The chosen most active H3R ligands 
described in this study were screened to identify beneficial 
and adverse ADME-Tox properties using in vitro methods 
imitating in vivo conditions and based on the eukaryotic and 
prokaryotic cell culture growths, HLMs, and bioluminescent 
enzymatic assays.
Metabolic stability
The metabolic stability of ligands 2, 4, 6, 7, and 14 was 
studied first in silico by the computational procedure
MetaSite.56 The most probably predicted site of metabolism 
(blue circle marked; Figure 5) was different depending on 
the respective structure investigated in this study. However, 
the piperidine and homopiperidine moieties were shown for 
all compounds as the sites with the very high probability 
of metabolic transformation (the darker red color of the 
marked functional group indicates its higher probability to 
be involved in the metabolism pathway; Figure 5), whereas 
according to in vitro data, among tested H3R ligands, the 
homopiperidine moiety of only compound 14 was involved in 
the reaction of biotransformation (Figures 5-7). In this study, 
the HLMs were used to determine in vitro the metabolic 
stability of H3R ligands. The UPLC analyses of the reaction 
mixtures after 120 min of 2, 4, 6, 7, and 14 incubation with 
HLMs are shown in Figure 6. Moreover, the number and 
molecular masses of the respective H3R ligands ’ metabolites, 
identified by MS analysis, are included in Table 3. The exact 
ion fragment analysis of the investigated compounds and their 
main metabolites (M1s) allowed to determine the primary 
metabolism pathways of the respective H3R ligands. As 
shown in Figure 7A-E, the M1s of compounds 2, 4, 6, and 7 
were obtained similarly by hydroxylation at the 4-substituted 
phenyl moieties. However, for compound 14, a different 
metabolism pathway was determined. According to the
F igure 5 The plot of MetaSite predictions for sites of metabolism of compounds 2, 4, 6, 7, and 14.
N otes: The darker color of the marked functional group indicates its higher probability to  be involved in the metabolic pathway. The blue circle marks the site of H3R ligand 
involved in metabolism with the highest probability calculated by MetaSite method.
A b b rev ia tio n : H3R, H3 receptor.
























































































3.82 790,378 26,103.71 2.98
3.86 2,373,908 68,067.02 7.77
4.02 796,672 28,674.02 3.27
5.82 5,987,492 667,762.38 76.25
6.24 2,801,603 85,110.95 9.72
1.00 2.00 3 .00 4.00 5.00 6.00 7 .00 8.00 9 .00 10.00 11.00 12.00













3.99 1,474,749 54,189.64 26.45
4.20 2,308,364 80,186.31 39.14
4.74 631,564 15,702.91 7.67
6.20 1,105,561 54,783.44 26.74



















4.29 1,727,762 55,551.36 2.71
4.74 7,397,531 260,586.33 12.73
6.07 17,646,634 1,601,866.13 78.23
6.22 3,160,889 116,404.06 5.68
7.09 564,417 13,193.59 0.64




















3.94 1,449,595 46,997.89 23.79
4.15 2,010,170 60,376.63 30.57
4.69 547,396 17,146.46 8.68
6.16 1,386,788 73,010.78 36.96
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3.60 753,742 18,822.87 2.15
3.64 1,601,365 44,060.44 5.02
4.50 684,987 19,594.72 2.23
4.91 866,744 23,776.77 2.71
4.96 2,031,782 58,354.86 6.66
5.59 3,406,640 126,091.58 14.38
6.07 8,836,873 539,204.63 61.50
6.23 1,658,244 46,919.19 5.35
1.00 2 .00  3 .00  4 .00  5 .00 6.00 7 .00 ¡.00 9 .00 10.00 11.00 12.00
Figure 6 The UPLC spectrum after 120 min reaction of 2, 4, 6, 7, and 14 with HLMs. 
A b brev ia tions: UPLC, ultra-performance liquid chromatography; HLMs, human liver microsomes.
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Table 3 The number of metabolites of selected H3R ligands and their molecular masses
H 3R N u m b e r of M olecu lar masses o f m etabolites
ligand m etabolites
2 3 m/z =306.24 (M l)* , m/z =306.30 (M2), m/z =306.30 (M3)
4 3 m/z =320.26 (M l)* , m/z =320.26 (M2), m/z =318.20 (M3)
6 2 m/z =354.22 (M l)* , m/z =370.24 (M2)
7 3 m/z =320.26 (M l)* , m/z =320.26 (M2), m/z =318.27 (M3)
14 5 m/z =358.21 (M l)*, m/z =342.19 (M2), m/z =360.20 (M3), m/z =342.19 (M4), m/z =374.16 (M5)
N o te : *Main metabolite. 
A b b rev ia tio n : H3R, H3 receptor.
precise analysis of the fragment ions produced by 14 and M 1, 
the main reaction of biotransformation of 14 includes two 
possibilities: double hydroxylation at the homopiperidine 
moiety and the degradation of homopiperidine moiety fol­
lowed by oxidation (Figure 7E). The second option would 
be in accordance with our data obtained previously for 1 
(PIT),57 where the degradation of the piperidine moiety of 
compound 1 followed by oxidation was observed as a main 
reaction of biotransformation.
Influence on recombinant human CYP3A4 and 2D6 
cytochromes activity
CYPs 3A4 and 2D6 are responsible for the metabolism 
of ~40%-50% of all marketed drugs; therefore, their potential 
inhibition may be a source of dangerous drug-drug interac­
tion (DDI).58 To predict potential DDI, ligands 2, 4, 6, 7, 
and 14 were examined to determine their influence on CYPs 
3A4 and 2D6 activity. For CYP 2D6, an additional study 
was performed for 1 (not included in Kuder et al57). To this 
purpose, we used the luminescence CYP3A4 and CYP2D6 
P450-Glo™ assays based on the conversion of the beetle 
D-luciferin derivative into D-luciferin by recombinant human 
CYPs 3A4 or 2D6 isoenzymes.38 As reference compounds, 
the following strong CYP inhibitors were used: CYP3A4 
inhibitor KE and CYP2D6 inhibitor QD. The CYP3A4 assay 
showed either very weak inhibition for ligands 2, 4, and 14 
or very weak induction of CYP3A4 cytochrome for ligands 
6 and 7 (Figure 8A). Similar to H3R ligands 2, 4, and 14, 
a very weak inhibition of CYP3A4 was also observed for 
ligand 1, which was described previously.57 Interestingly, 
almost all examined H3R ligands showed strong effect on 
2D6 cytochrome at the high concentrations of >2.5 |J.M. 
Surprisingly, no effect on CYP2D6 for the lead structure 2, 
with the shorter, aliphatic linker was shown (Figure 8B).
Safety profile
The preliminary evaluation of safety profile for the H3R 
ligands 2, 4, 6, 7, and 14 was performed by the formazan
dye-based EZ4U assay, which determines the influence of 
the examined compounds on the proliferation of eukaryotic 
cell lines and by Ames MPF assay to evaluate the risk of 
genotoxic effect. To determine the antiproliferative effect, 
the human embryonic cell line (HEK-293) was incubated in 
the presence of H3R ligands for 48 h. The antiproliferative 
drug DX was used as a reference. All tested H3R ligands, 
excluded 2, showed weak antiproliferative effect on exam­
ined cell line in IC50 range from 11.82 p.M (14) to 33.26 |J.M 
(7). However, for compound 2, the antiproliferative effect 
was observed only at the highest concentration of 250 |J.M 
(Figure 8C). Furthermore, S. typhimurium strain TA98 was 
used for the evaluation of potential genotoxicity of promis­
ing H3R ligands. Strain TA98 is incapable of producing 
histidine, but mutagenic events may lead to reverse mutation 
that allows reverted bacteria to grow in histidine-deficient 
media. The criteria used to evaluate Ames MPF test result in 
a number of revertants after the exposure to tested chemicals. 
The increase of revertants is calculated relative to solvent 
control baseline (FIB), and the threshold value of FIB equal 
to 2.0 is considered as a cutoff parameter for the identification 
of potential mutagens. In this experiment, the H3R ligands 
2, 4, 6, 7, and 14 were tested in two concentrations, 1 and 
10 pM, and NQNO at 0.5 pM was used as a positive control. 
As depicted in Figure 9, none of the tested H3R ligands 
showed the genotoxic effect in Ames MPF test.
Conclusion
In the current series of H3R ligands, compounds with prom­
ising nanomolar affinity were obtained. While elongation 
of alkyl spacer length in the examined group of phenoxy- 
alkylamine derivatives (as compared to DL-77 [2]) signifi­
cantly influences the antagonist affinities of the investigated 
compounds for hH3R, the highest affinities were observed 
for 3-methylpiperidine derivative 6 (hH3R K  values of 
27.3±15.1 nM) with five carbons alkyl chain. Likewise, the 
character of the respective cyclic amine had an enormous 
effect on the affinity of the evaluated H3R ligands with
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F igure 7 (A ) Ion fragm ent analysis and probable s truc tu re  o f the  main m etabolite M I o f com pound 2. (B) Ion fragm ent analysis and probable s truc tu re  o f the main metabolite M I o f compound 4. (C ) Ion fragm ent analysis and probable 
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F igure 8 (A ) Effect of KE and compounds 2, 4, 6, 7, and 14 on CYP3A4 activity. (B) Effect of Q D  and compounds 1, 2, 4, 6, 7, and 14 on CYP2D6 activity. (C ) Activity of 
the reference D X  and compounds 2, 4, 6, 7, and 14 against HEK-293 cell line.
A b brev ia tions: KE, ketoconazole; CYP, cytochrome P450; Q D , quinidine; DX, doxorubicin; HEK, human embryonic kidney.
3-methylpiperidine derivatives being the most potent for 
this group. The results of the in vivo anticonvulsive testing 
revealed that compounds 4 and 14 showed promising protec­
tive effects subsequent to acute systemic administration in 
the STR-, PTZ-, and MES-induced seizure models, respec­
tively. Notably, the protective effect found for ligand 14 in 
the MES-induced seizure model was entirely abolished when 
rats were pretreated with the CNS-penetrant H1R antagonist 
PYR, however, not with the centrally acting H2R antagonist 
ZOL, demonstrating that H1Rs histaminergic pathways 
seem to be involved in the provided anticonvulsant activ­
ity observed for H3R ligand 14. On the contrary, PYR and 
ZOL failed to abrogate the protective effects provided by 4 
in the PTZ- and STR-induced seizure models, respectively. 









F igure 9 increase of histidine prototrophy revertants over baseline for Salmonella 
typhimurium strain TA98, exposed to H3R ligands (1 or 10 |tM ) or reference mutagen 
N Q N O  (0.5 |tM).
N o te : assay was performed in triplicates.
A b brev ia tions: H3R, H3 receptor; N Q N O , nonyl-4-hydroxyquinoline-N-oxide.
satisfying, selected ADME-Tox parameters. The metabolic 
stability and main metabolic pathways were evaluated. No 
genotoxic and weak cytotoxic effect in comparison to the 
reference drug DX was shown. Moreover, very weak influ­
ence on CYP3A4 and strong influence on CYP2D6, but only 
in the highest concentrations, were observed. Unlike the H3R 
ligands with long aliphatic chain, for the lead structure 2, 
no antiproliferative and no mutagenic effects, as well as no 
influence on examined CYPs, were observed.
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